CTAD 2025 | The development of plasma biomarker clocks to predict AD symptom onset

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, comments on the development of plasma biomarker clocks to predict the onset of Alzheimer’s disease (AD) symptoms. Dr Schindler highlights that plasma pTau217 is a good marker of pathology, and that the age at which pathology starts to accumulate is a strong predictor of when symptoms will start. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.